AGY Stock Overview
A commercial biotechnology company, engages in the research and development of allergy treatments.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Allergy Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.056 |
52 Week High | UK£0.063 |
52 Week Low | UK£0.012 |
Beta | 1.46 |
11 Month Change | 6.67% |
3 Month Change | 111.32% |
1 Year Change | 173.17% |
33 Year Change | -79.14% |
5 Year Change | -52.34% |
Change since IPO | -92.48% |
Recent News & Updates
Shareholder Returns
AGY | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0.4% | -0.8% | -1.2% |
1Y | 173.2% | 11.5% | 4.4% |
Return vs Industry: AGY exceeded the UK Pharmaceuticals industry which returned 12.3% over the past year.
Return vs Market: AGY exceeded the UK Market which returned 5.4% over the past year.
Price Volatility
AGY volatility | |
---|---|
AGY Average Weekly Movement | 9.6% |
Pharmaceuticals Industry Average Movement | 7.4% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.7% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AGY's share price has been volatile over the past 3 months.
Volatility Over Time: AGY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 612 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut.
Allergy Therapeutics plc Fundamentals Summary
AGY fundamental statistics | |
---|---|
Market cap | UK£262.15m |
Earnings (TTM) | -UK£50.22m |
Revenue (TTM) | UK£53.26m |
5.0x
P/S Ratio-5.3x
P/E RatioIs AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGY income statement (TTM) | |
---|---|
Revenue | UK£53.26m |
Cost of Revenue | UK£25.28m |
Gross Profit | UK£27.98m |
Other Expenses | UK£78.20m |
Earnings | -UK£50.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.011 |
Gross Margin | 52.54% |
Net Profit Margin | -94.29% |
Debt/Equity Ratio | 6.0% |
How did AGY perform over the long term?
See historical performance and comparison